AR125304A1 - Compuestos de oxazepina acíclicos y usos de los mismos - Google Patents
Compuestos de oxazepina acíclicos y usos de los mismosInfo
- Publication number
- AR125304A1 AR125304A1 ARP220100858A ARP220100858A AR125304A1 AR 125304 A1 AR125304 A1 AR 125304A1 AR P220100858 A ARP220100858 A AR P220100858A AR P220100858 A ARP220100858 A AR P220100858A AR 125304 A1 AR125304 A1 AR 125304A1
- Authority
- AR
- Argentina
- Prior art keywords
- acyclic
- oxazepine compounds
- oxazepine
- compounds
- atropisomer
- Prior art date
Links
- 150000000221 oxazepines Chemical class 0.000 title 1
- -1 Acyclic oxazepine compounds Chemical class 0.000 abstract 1
- 101150020251 NR13 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
En la presente se proporcionan compuestos acíclicos de oxazepina útiles en el tratamiento de cánceres. Un compuesto que tiene la fórmula (1), o un estereoisómero, atropisómero, tautómero o sal farmacéuticamente aceptable de este, en dónde; X es NR¹³, O, C(Rˣ)₂, C(O), SO, SO₂ o S; u es 1 o 2; en donde R¹, R², R³, R⁴, R⁵, R⁶ y R⁶A son como se definen en la reivindicación 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021085959 | 2021-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125304A1 true AR125304A1 (es) | 2023-07-05 |
Family
ID=81387302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100858A AR125304A1 (es) | 2021-04-08 | 2022-04-06 | Compuestos de oxazepina acíclicos y usos de los mismos |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240383915A1 (es) |
| EP (1) | EP4320132A1 (es) |
| JP (1) | JP2024513881A (es) |
| KR (1) | KR20230167386A (es) |
| CN (1) | CN117083279A (es) |
| AR (1) | AR125304A1 (es) |
| AU (1) | AU2022254674A1 (es) |
| BR (1) | BR112023020773A2 (es) |
| CA (1) | CA3215949A1 (es) |
| MX (1) | MX2023011873A (es) |
| TW (1) | TWI868441B (es) |
| WO (1) | WO2022216762A1 (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| CA3244383A1 (en) | 2022-03-11 | 2023-09-14 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND RELATED USES |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| JP2025525946A (ja) | 2022-08-05 | 2025-08-07 | カムクワット バイオサイエンシーズ インコーポレイテッド | 複素環式化合物およびその使用 |
| CA3264226A1 (en) * | 2022-08-11 | 2024-02-15 | Beigene Switzerland Gmbh | HETEROCYCLIC COMPOUNDS, COMPOSITIONS BASED THEREON AND ASSOCIATED PROCESSING METHODS |
| WO2024041573A1 (en) * | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| AR130796A1 (es) * | 2022-10-18 | 2025-01-22 | Ildong Pharmaceutical Co Ltd | Compuestos triheterocíclicos novedosos |
| EP4605399A1 (en) * | 2022-10-19 | 2025-08-27 | Genentech Inc. | Oxazepine compounds comprising a 6-aza moiety and uses thereof |
| IL320913A (en) | 2022-11-21 | 2025-07-01 | Treeline Biosciences Inc | Spirocyclic dihydropyranopyrimidine KRAS inhibitors |
| WO2024153180A1 (zh) * | 2023-01-18 | 2024-07-25 | 上海艾力斯医药科技股份有限公司 | 杂环类化合物、其药物组合物及其用途 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| WO2024197503A1 (en) * | 2023-03-27 | 2024-10-03 | Nikang Therapeutics , Inc. | Tricyclic derivatives as kras inhibitors |
| TW202504611A (zh) | 2023-03-30 | 2025-02-01 | 美商銳新醫藥公司 | 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途 |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| AU2024243852A1 (en) | 2023-04-07 | 2025-11-06 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| TW202509040A (zh) * | 2023-05-16 | 2025-03-01 | 大陸商和記黃埔醫藥（上海）有限公司 | 三環類化合物及其用途 |
| WO2024254334A1 (en) * | 2023-06-06 | 2024-12-12 | Kumquat Biosciences Inc. | Substituted heterocycles and uses thereof |
| TW202502779A (zh) * | 2023-06-30 | 2025-01-16 | 美商金橘生物科技公司 | 取代的雜芳族胺及其用途 |
| CN116903499B (zh) * | 2023-07-11 | 2025-05-30 | 上海应用技术大学 | 无水氟磺酰基二氟乙酸铜盐及其制备方法与应用 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202515570A (zh) | 2023-08-17 | 2025-04-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并嘧啶ｋｒａｓ抑制劑 |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025096738A1 (en) * | 2023-11-01 | 2025-05-08 | Incyte Corporation | Kras inhibitors |
| WO2025111586A1 (en) | 2023-11-22 | 2025-05-30 | Genentech, Inc. | Polymorphs of and synthetic process for an aza-tetracyclic oxazepine inhibitor of kras-g12d |
| TW202527946A (zh) * | 2023-12-19 | 2025-07-16 | 大陸商正大天晴藥業集團股份有限公司 | 三并環類化合物及其醫藥用途 |
| WO2025167948A1 (zh) * | 2024-02-06 | 2025-08-14 | 上海齐鲁制药研究中心有限公司 | 嘧啶并大环类kras抑制剂 |
| WO2025168072A1 (en) * | 2024-02-08 | 2025-08-14 | Beigene (Suzhou) Co., Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| MA46092A (fr) * | 2016-08-31 | 2021-04-21 | Agios Pharmaceuticals Inc | Inhibiteurs de processus métaboliques cellulaires |
| AR111776A1 (es) * | 2017-05-11 | 2019-08-21 | Astrazeneca Ab | Heteroarilos inhibidores de las proteínas ras mutantes de g12c |
| TW202012415A (zh) * | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| SG11202109451TA (en) * | 2019-03-05 | 2021-09-29 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| CN112574224A (zh) * | 2019-09-30 | 2021-03-30 | 上海迪诺医药科技有限公司 | Kras g12c抑制剂及其应用 |
-
2022
- 2022-04-06 AU AU2022254674A patent/AU2022254674A1/en active Pending
- 2022-04-06 CN CN202280026974.XA patent/CN117083279A/zh active Pending
- 2022-04-06 BR BR112023020773A patent/BR112023020773A2/pt unknown
- 2022-04-06 JP JP2023561271A patent/JP2024513881A/ja active Pending
- 2022-04-06 CA CA3215949A patent/CA3215949A1/en active Pending
- 2022-04-06 EP EP22719149.1A patent/EP4320132A1/en active Pending
- 2022-04-06 KR KR1020237037698A patent/KR20230167386A/ko active Pending
- 2022-04-06 US US18/554,438 patent/US20240383915A1/en active Pending
- 2022-04-06 AR ARP220100858A patent/AR125304A1/es unknown
- 2022-04-06 TW TW111113063A patent/TWI868441B/zh active
- 2022-04-06 WO PCT/US2022/023573 patent/WO2022216762A1/en not_active Ceased
- 2022-04-06 MX MX2023011873A patent/MX2023011873A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023011873A (es) | 2023-10-17 |
| CN117083279A (zh) | 2023-11-17 |
| CA3215949A1 (en) | 2022-10-13 |
| KR20230167386A (ko) | 2023-12-08 |
| WO2022216762A1 (en) | 2022-10-13 |
| JP2024513881A (ja) | 2024-03-27 |
| TWI868441B (zh) | 2025-01-01 |
| TW202304934A (zh) | 2023-02-01 |
| US20240383915A1 (en) | 2024-11-21 |
| AU2022254674A1 (en) | 2023-10-12 |
| BR112023020773A2 (pt) | 2024-01-30 |
| EP4320132A1 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125304A1 (es) | Compuestos de oxazepina acíclicos y usos de los mismos | |
| AR130727A1 (es) | Compuestos tricíclicos y sus usos | |
| AR054809A1 (es) | Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa | |
| AR122628A1 (es) | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8 | |
| AR121226A1 (es) | Compuestos y usos de estos | |
| AR027406A1 (es) | Moduladores de receptores canabinoides, sus procesos de preparacion y uso de los moduladores de receptores canabinoides para el tratamiento de enfermedadesrespiratorias y no respiratorias. | |
| AR088919A2 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y uso | |
| AR114489A1 (es) | ANTAGONISTAS DE LA INTEGRINA a4b7 HUMANA | |
| AR053120A1 (es) | Aminopiridinas como inhibidores de beta secretasa | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| PE20242071A1 (es) | Compuestos moduladores de diacilglicerol quinasa | |
| AR121777A1 (es) | Derivados de diamina macrocíclica como inhibidores de ent para el tratamiento de cánceres, y combinación de estos con antagonistas del receptor de adenosina | |
| AR008290A1 (es) | Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios. | |
| AR045805A1 (es) | Quinolonas y naftridonas 7- amino alquidenil - heterociclicas | |
| AR131158A1 (es) | Compuestos que inhiben la pkmyt1 | |
| ES2095942T3 (es) | Derivados de bencenoacetamida inhibidores del vih. | |
| MX9307946A (es) | Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso. | |
| AR124008A1 (es) | 1,4-diazepanonas bicíclicas y sus usos terapéuticos | |
| AR131278A1 (es) | Compuestos novedosos | |
| AR042002A1 (es) | Benzoxazinonas sustituidas, proceso de obtencion y usos para tratamiento de enfermedades del sistema nervioso central. | |
| DOP2025000069A (es) | Inhibidores de sik novedosos | |
| PE20031038A1 (es) | Compuestos triciclicos como inhibidores de la farnesil proteina transferasa | |
| CL2024001298A1 (es) | Compuestos de cd73 | |
| ES2075976T3 (es) | Derivados de aminoacido y su empleo como agentes antiviricos. |